CompanyDeals

Sun-Novo and GemPharmatech Sign Long‑Term Strategic Cooperation Agreement to Deepen Preclinical Collaboration on Small Nucleic Acid Therapeutics and Build Closed‑Loop AOC R&D System

CompanyDeals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

CompanyDrug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

CompanyDrug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

CompanyDeals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

CompanyDrug

CSPC Pharmaceutical Group’s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US

CompanyDeals

Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI

CompanyDeals

Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D

CompanyDeals

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

BeOne Medicines Announces Imdelltra (Tarlatamab), First‑in‑Class DLL3/CD3 T‑Cell Engager Co‑Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities
CompanyDrug

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

CompanyDeals

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

CompanyDrug

Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms